|
1
|
Huang H, Peng X and Zhong C: Idiopathic
pulmonary fibrosis: The current status of its epidemiology,
diagnosis, and treatment in China. Intractable Rare Dis Res.
2:88–93. 2013.PubMed/NCBI
|
|
2
|
Loveman E, Copley VR, Scott DA, Colquitt
JL, Clegg AJ and O'Reilly KM: Comparing new treatments for
idiopathic pulmonary fibrosis-a network meta-analysis. BMC Pulm
Med. 15:372015. View Article : Google Scholar
|
|
3
|
Lynch JP III, Huynh RH, Fishbein MC,
Saggar R, Belperio JA and Weigt SS: Idiopathic Pulmonary fibrosis:
Epidemiology, clinical features, prognosis, and management. Semin
Respir Crit Care Med. 37:331–357. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
King TE Jr, Pardo A and Selman M:
Idiopathic pulmonary fibrosis. Lancet. 378:1949–1961. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Strookappe B, Elfferich M, Swigris J,
Verschoof A, Veschakelen J, Knevel T and Drent M: Benefits of
physical training in patients with idiopathic or end-stage
sarcoidosis-related pulmonary fibrosis: A pilot study. Sarcoidosis
Vasc Diffuse Lung Dis. 32:43–52. 2015.PubMed/NCBI
|
|
6
|
Dempsey OJ, Kerr KM, Gomersall L, Remmen H
and Currie GP: Idiopathic pulmonary fibrosis: An update. QJM.
99:643–654. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spagnolo P, Rossi G and Cavazza A:
Pathogenesis of idiopathic pulmonary fibrosis and its clinical
implications. Expert Rev Clin Immunol. 10:1005–1017. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Collard HR, Ryerson CJ, Corte TJ, Jenkins
G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM,
et al: Acute exacerbation of idiopathic pulmonary fibrosis. An
International Working Group Report. Am J Respir Crit Care Med.
194:265–275. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fernández Pérez ER, Daniels CE, Schroeder
DR, St Sauver J , Hartman TE, Bartholmai BJ, Yi ES and Ryu JH:
Incidence, prevalence, and clinical course of idiopathic pulmonary
fibrosis: A population-based study. Chest. 137:129–137. 2010.
View Article : Google Scholar
|
|
10
|
Finger JN, Lich JD, Dare LC, Cook MN,
Brown KK, Duraiswami C, Bertin J and Gough PJ: Autolytic
proteolysis within the function to find domain (FIIND) is required
for NLRP1 inflammasome activity. J Biol Chem. 287:25030–25037.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saresella M, La Rosa F, Piancone F, Zoppis
M, Marventano I, Calabrese E, Rainone V, Nemni R, Mancuso R and
Clerici M: The NLRP3 and NLRP1 inflammasomes are activated in
Alzheimer's disease. Mol Neurodegener. 11:232016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
D'Osualdo A and Reed JC: NLRP1, a
regulator of innate immunity associated with vitiligo. Pigment Cell
Melanoma Res. 25:5–8. 2012. View Article : Google Scholar
|
|
13
|
Levandowski CB, Mailloux CM, Ferrara TM,
Gowan K, Ben S, Jin Y, McFann KK, Holland PJ, Fain PR, Dinarello CA
and Spritz RA: NLRP1 haplotypes associated with vitiligo and
autoimmunity increase interleukin-1β processing via the NLRP1
inflammasome. Proc Natl Acad Sci USA. 110:2952–2956. 2013.
View Article : Google Scholar
|
|
14
|
Wang YC, Li WZ, Wu Y, Yin YY, Dong LY,
Chen ZW and Wu WN: Acid-sensing ion channel 1a contributes to the
effect of extracellular acidosis on NLRP1 inflammasome activation
in cortical neurons. J Neuroinflammation. 12:2462015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vandanmagsar B, Youm YH, Ravussin A,
Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM and Dixit
VD: The NLRP3 inflammasome instigates obesity-induced inflammation
and insulin resistance. Nat Med. 17:179–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rastrick J and Birrell M: The role of the
inflammasome in fibrotic respiratory diseases. Minerva Med.
105:9–23. 2014.PubMed/NCBI
|
|
17
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals: Guide for the care and use of laboratory animals. Eighth
Edition. Guide for the Care and Use of Laboratory Animals, National
Academies Press (US); Washington: 103. pp. 1072–1073. 2010
|
|
18
|
Li Y, Gao J, Wang G and Fei G: Latent
cytomegalovirus infection exacerbates experimental pulmonary
fibrosis by activating TGF-β1. Mol Med Rep. 14:1297–1301. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Banczyk D, Kalies K, Nachbar L, Bergmann
L, Schmidt P, Bode U, Teegen B, Steven P, Lange T, Textor J, et al:
Activated CD4+ T cells enter the splenic T-cell zone and
induce autoantibody-producing germinal centers through bystander
activation. Eur J Immunol. 44:93–102. 2014. View Article : Google Scholar
|
|
20
|
Szapiel SV, Elson NA, Fulmer JD,
Hunninghake GW and Crystal RG: Bleomycin-induced interstitial
pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis.
120:893–899. 1979.PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Labzin LI, Lauterbach MA and Latz E:
Interferons and inflammasomes: Cooperation and counterregulation in
disease. J Allergy Clin Immunol. 138:37–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Walsh JG, Muruve DA and Power C:
Inflammasomes in the CNS. Nat Rev Neurosci. 15:84–97. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Masood H: Inflammasomes in the
pathophysiology of kidney diseases. Kidney Dis (Basel). 1:187–193.
2015. View Article : Google Scholar
|
|
25
|
Yang CA and Chiang BL: Inflammasomes and
human autoimmunity: A comprehensive review. J Autoimmun. 61:1–8.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sierro S, Rothkopf R and Klenerman P:
Evolution of diverse antiviral CD8+ T cell populations
after murine cytomegalovirus infection. Eur J Immunol.
35:1113–1123. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Restrepo-Gualteros SM, Jaramillo-Barberi
LE, Gonzalez-Santos M, Rodriguez-Martinez CE, Perez GF, Gutierrez
MJ and Nino G: Characterization of cytomegalovirus lung infection
in non-HIV infected children. Viruses. 6:2038–2051. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hoshino T, Nakamura H, Okamoto M, Kato S,
Araya S, Nomiyama K, Oizumi K, Young HA, Aizawa H and Yodoi J:
Redox-active protein thioredoxin prevents proinflammatory cytokine-
or bleomycin-induced lung injury. Am J Respir Crit Care Med.
168:1075–1083. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boger DL and Cai H: Bleomycin: Synthetic
and mechanistic studies. Angewandte Chemie Int Edition. 38:448–476.
2010. View Article : Google Scholar
|
|
30
|
Gwinn WM, Kapita MC, Wang PM, Cesta MF and
Martin WJ II: Synthetic liposomes are protective from
bleomycin-induced lung toxicity. Am J Physiol Lung Cell Mol
Physiol. 301:L207–L217. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hofman K, Hall B, Cleaver H and Marshall
S: High-throughput quantification of hydroxyproline for
determination of collagen. Anal Biochem. 417:289–291. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhan H, Huang F, Ma W, Zhao Z, Zhang H and
Zhang C: Protective effect of ginsenoside Rg1 on bleomycin-induced
pulmonary fibrosis in rats: Involvement of caveolin-1 and TGF-β1
signal pathway. Biol Pharm Bull. 39:1284–1292. 2016. View Article : Google Scholar
|
|
33
|
Banczyk D, Kalies K, Nachbar L, Bergmann
L, Schmidt P, Bode U, Teegen B, Steven P, Lange T, Textor J, et al:
Activated CD4+ T cells enter the splenic T-cell zone and
induce autoantibody-producing germinal centers through bystander
activation. Eur J Immunol. 44:93–102. 2014. View Article : Google Scholar
|
|
34
|
Guarda G, Dostert C, Staehli F, Cabalzar
K, Castillo R, Tardivel A, Schneider P and Tschopp J: T cells
dampen innate immune responses through inhibition of NLRP1 and
NLRP3 inflammasomes. Nature. 460:269–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Viganò E and Mortellaro A: Caspase-11: The
driving factor for noncanonical inflammasomes. Eur J Immunol.
43:2240–2245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheresh P, Kim SJ, Tulasiram S and Kamp
DW: Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta.
1832:1028–1040. 2013. View Article : Google Scholar :
|
|
37
|
Saïd-Sadier N and Ojcius DM: Alarmins,
inflammasomes and immunity. Biomed J. 35:437–449. 2012. View Article : Google Scholar
|
|
38
|
Gasse P, Mary C, Guenon I, Noulin N,
Charron S, Schnyder-Candrian S, Schnyder B, Akira S, Quesniaux VF,
Lagente V, et al: IL-1R1/MyD88 signaling and the inflammasome are
essential in pulmonary inflammation and fibrosis in mice. J Clin
Invest. 117:3786–3799. 2007.PubMed/NCBI
|
|
39
|
Guerville F, Daburon S, Marlin R, Lartigue
L, Loizon S, Pitard V, Couzi L, Moreau JF, Déchanet-Merville J and
Faustin B: TCR-dependent sensitization of human gammadelta T cells
to non-myeloid IL-18 in cytomegalovirus and tumor stress
surveillance. Oncoimmunology. 4:e10030112015. View Article : Google Scholar
|
|
40
|
Schroder K and Tschopp J: The
inflammasomes. Cell. 140:821–832. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mankan AK, Kubarenko A and Hornung V:
Immunology in clinic review series; focus on autoinflammatory
diseases: Inflammasomes: Mechanisms of activation. Clin Exp
Immunol. 167:369–381. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bromley SK, Mempel TR and Luster AD:
Orchestrating the orchestrators: Chemokines in control of T cell
traffic. Nat Immunol. 9:970–980. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Luzina IG, Todd NW, Sundararajan S and
Atamas SP: The cytokines of pulmonary fibrosis: Much learned, much
more to learn. Cytokine. 74:88–100. 2015. View Article : Google Scholar
|
|
44
|
Zhou XM, Wen GY, Zhao Y, Liu YM and Li JX:
Inhibitory effects of alkaline extract of Citrus reticulata on
pulmonary fibrosis. J Ethnopharmacol. 146:372–378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yu HB and Finlay BB: The caspase-1
inflammasome: A pilot of innate immune responses. Cell Host
Microbe. 4:198–208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kong H, Wang Y, Zeng X, Zhu Q, Xie W and
Dai S: Involvement of NLRP3 inflammasome in rituximab-induced
interstitial lung disease: A case report. J Clin Pharm Ther.
39:691–694. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
De Nardo D, De Nardo CM and Latz E: New
insights into mechanisms controlling the NLRP3 inflammasome and its
role in lung disease. Am J Pathol. 184:42–54. 2014. View Article : Google Scholar :
|
|
48
|
Artlett CM, Sassi-Gaha S, Rieger JL,
Boesteanu AC, Feghali-Bostwick CA and Katsikis PD: The inflammasome
activating caspase 1 mediates fibrosis and myofibroblast
differentiation in systemic sclerosis. Arthritis Rheum.
63:3563–3574. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huang TT, Lai HC, Ko YF, Ojcius DM, Lan
YW, Martel J, Young JD and Chong KY: Hirsutella sinensis mycelium
attenuates bleomycin-induced pulmonary inflammation and fibrosis in
vivo. Sci Rep. 5:152822015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dostert C, Pétrilli V, Van Bruggen R,
Steele C, Mossman BT and Tschopp J: Innate immune activation
through Nalp3 inflammasome sensing of asbestos and silica. Science.
320:674–677. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xu JF, Washko GR, Nakahira K, Hatabu H,
Patel AS, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC,
et al: Statins and pulmonary fibrosis: The potential role of NLRP3
inflammasome activation. Am J Respir Crit Care Med. 185:547–556.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tong CY, Bakran A, Williams H, Cuevas LE,
Peiris JS and Hart CA: Association of tumour necrosis factor alpha
and interleukin 6 levels with cytomegalovirus DNA detection and
disease after renal transplantation. J Med Virol. 64:29–34. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Contreras A, Botero JE and Slots J:
Biology and pathogenesis of cytomegalovirus in periodontal disease.
Periodontol 2000. 64:40–56. 2014. View Article : Google Scholar
|
